arrow
D

Desirée Hao

arthur j.e. child comprehensive cancer centre and cumming school of medicine
H指数:29
被引数:2,379

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib

SAVANNAH研究的大众语言摘要:色瑞替尼联合奥希替尼用于EGFR突变型晚期非小细胞肺癌患者,这些患者的肿瘤在奥希替尼治疗后出现MET过表达和/或扩增,且肿瘤已进展或扩散。

2026-07-160
OA
Effects of serotonergic drugs on immune checkpoint inhibitor response: a pooled analysis of individual patient data from four Canadian Cancer Trials Group (CCTG) trials

5-羟色胺能药物对免疫检查点抑制剂反应的影响:一项基于四项加拿大癌症试验组(CCTG)试验的患者个体数据的合并分析

2025-11-010
PRE
A phase I study of binimetinib, a MEK inhibitor, in combination with pembrolizumab in patients with advanced non-small cell lung cancer (NSCLC)
2023-04-142
PRE
The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer
2022-07-2621
OAAI
ACCURACY: A phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut): Results of 6-mg cohort
2021-09-015
OAAI
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies

加拿大癌症试验组IB期研究durvalumab (anti-PD-L1) 联合tremelimumab (anti-CTLA-4) 同时或顺序给予晚期,无法治愈的实体恶性肿瘤患者

2020-02-040
PREAI